

# Taking Microbiome Analysis to the Next Level

## Next Generation Sequencing (NGS) with State-of-the-Art Technology

Dear colleagues,  
dear members of the medical practice team,

We are pleased to inform you that we have replaced our trusted Illumina MiSeq sequencers in our molecular biology laboratory with the **brand-new Illumina MiSeq i100 generation**. This upgrade once again sets new standards in terms of **speed, precision, and data quality** for your microbiome analyses.

Your benefits at a glance:

- **Reduced turnaround times::**

With optimised reagents, improved sequencing protocols, and cutting-edge bioinformatics, report turnaround times are reduced by up to 30%. This means that you receive results more quickly and can make timely decisions and initiate targeted therapies faster.

- **Improved workflows:**

State-of-the-art hardware and standardised protocols ensure **consistently reliable results – from initial diagnostics through to therapy monitoring**.

- **Superior data quality:**

The new sequencing platforms deliver even more consistent read quality, thereby enabling **more precise taxonomic and functional analyses**.

What is changing?

With the transition, our reference ranges will also be updated as of **1 August 2025**:

- The new reference ranges have been established on the upgraded systems through a **current reference value study** using an appropriate cohort.
- Please note: **Individual values** will not be directly comparable with those from previous analyses.

**However:**

- The **format** and **interpretation of the reports** will remain unchanged. The new reference ranges will automatically be taken into account when interpreting findings. Therefore, key interpretations (e.g. diversity normal or reduced) will **remain comparable between old and new reports**.

**Any questions?**

Our **customer service team** is available via email at [info@ganzimmun.de](mailto:info@ganzimmun.de) or by phone on **+49 6131 7205-0, Monday to Friday between 8 a.m. and 7 p.m.**

We look forward to continuing our successful collaboration.

With collegial regards



Dr. med. Zickgraf  
and the team at GANZIMMUN